News

MedPage Today on MSN9h
FDA Restricts Use of Immunotherapies in Gastric, Esophageal Cancers
Now, nivolumab -- in combination with chemotherapy -- is indicated for the first-line treatment of adults with unresectable ...
GlobalData on MSN18h
Daiichi announces first subject dosing in Enhertu trial for endometrial cancer
The study will be carried out in partnership with The GOG Foundation and the European Network of Gynecological Oncological ...
Applied Clinical Trials Online8h
First Patient Dosed in Phase III Trial of Enhertu as First-Line Treatment for Endometrial Cancer
In combination with rilvegostomig or Keytruda, Enhertu will be evaluated versus chemotherapy in the DESTINY-Endometrial01 ...
pharmaphorum19h
MSD moves ahead in race to bring oral PCSK9 drug to market
Currently available PCSK9-targeting therapies are Amgen's Repatha (evolocumab) and Sanofi/Regeneron's Praluent (alirocumab), ...
Merck & Co., Inc. (MRK) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript
Merck & Co., Inc. ( NYSE: MRK) Goldman Sachs 46th Annual Global Healthcare Conference June 10, 2025 10:00 AM ET Dean Y. Li - Executive VP & President of Merck Research Laboratories Robert M. Davis - ...
Physician's Weekly9h
Biomarker-Guided Adjuvant Treatment Supports Real-World Survival in Early NSCLC
Biomarker-targeted adjuvant therapy improved survival in early-stage NSCLC, highlighting the importance of testing and ...